Morgan Stanley Maintains Equal-Weight on ThredUp, Lowers Price Target to $1
Morgan Stanley analyst Lauren Schenk maintains ThredUp (NASDAQ:TDUP) with a Equal-Weight and lowers the price target from $1.75 to $1.
Piper Sandler Maintains Neutral on ThredUp, Lowers Price Target to $2
Piper Sandler analyst Edward Yruma maintains ThredUp (NASDAQ:TDUP) with a Neutral and lowers the price target from $3.5 to $2.
ThredUp Sees Q4 Revenue $62M-$64M Vs $71.17M Est.; Sees FY22 Revenue $279M-$281M Vs $285.64M Est.
Financial Outlook
For the fourth quarter 2022, thredUP expects:
Revenue in the range of $62 million to $64 million
Gross margin in the range of 62.0% to 64.0%
Adjusted
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell
• Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
Where ThredUp Stands With Analysts
Over the past 3 months, 6 analysts have published their opinion on ThredUp (NASDAQ:TDUP) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 517 companies set new 52-week lows.